Otsuka (OTCMKTS:OTSKY) Trading 2.2% Higher - What's Next?

Key Points

• Otsuka Holdings Co., Ltd. shares increased by 2.2%, reaching a last traded price of $26.67 with a significant volume surge compared to the average session.
• Analyst ratings have shifted, with Zacks Research downgrading Otsuka to a "strong sell", contributing to an overall average rating of "Sell" among analysts.
• The company operates in various sectors including pharmaceuticals, nutraceuticals, and consumer products, with a market capitalization of $28.65 billion and a low price-to-earnings ratio of 0.18.

Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report) shares traded up 2.2% during mid-day trading on Tuesday . The company traded as high as $26.70 and last traded at $26.67. 111,197 shares were traded during mid-day trading, an increase of 248% from the average session volume of 31,924 shares. The stock had previously closed at $26.10.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Otsuka to a "strong sell" rating in a research report on Monday, August 11th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of "Sell".

Otsuka Stock Performance

The company has a fifty day simple moving average of $26.61 and a 200 day simple moving average of $25.12. The stock has a market capitalization of $28.65 billion and a price-to-earnings ratio of 0.18.

Otsuka Company Profile

Otsuka Holdings Co, Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.